肿瘤细胞治疗研究
英文原题：Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics.
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics.
这些发现凸显了单细胞技术在揭示TME复杂性、识别治疗应答生物标志物以及指导RCC精准免疫治疗方面的变革性潜力。
肾细胞癌（RCC）的结局由复杂的肿瘤微环境（TME）塑造，其中恶性细胞仅占组织的一小部分。单细胞技术的最新进展——包括单细胞 RNA 测序、单核 RNA 测序、单细胞转座酶可及性染色质测序、单细胞 T 细胞受体测序和成像质谱流式——揭示了 RCC 的细胞、调控和空间异质性。在此，我们综合这些方法的见解，以定义多样的 CD8+ T 细胞亚群和耗竭轨迹，以及其他免疫细胞（包括肿瘤相关巨噬细胞、树突状细胞、NK 细胞和癌症相关成纤维细胞）的起源、表型多样性和功能状态。总之，这些发现凸显了单细胞技术在揭示 TME 复杂性、识别治疗反应生物标志物以及指导 RCC 精准免疫治疗方面的变革性潜力。
Renal cell carcinoma (RCC) outcomes are shaped by a complex tumor microenvironment (TME), where malignant cells represent only a minority of the tissue. Recent advances in single-cell technologies - including single-cell RNA sequencing, single-nucleus RNA sequencing, single-cell assay for transposase-accessible chromatin sequencing, single-cell T-cell receptor sequencing, and imaging mass cytometry - have uncovered the cellular, regulatory, and spatial heterogeneity of RCC. Here, we synthesize insights from these approaches to define diverse CD8 + T-cell subsets and exhaustion trajectories, as well as the origins, phenotypic diversity, and functional states of other immune cells including tumor-associated macrophages, dendritic cells, natural killer cells and cancer-associated fibroblasts. Together, these findings highlight the transformative potential of single-cell technologies to unravel TME complexity, identify biomarkers of therapeutic response, and guide precision immunotherapy in RCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
